pSivida Announces Resubmission of New Drug Application for Iluvien
Links shared publicly online about this topic.
- 295total visits
pSivida Announces Resubmission of New Drug Application for Iluvien
View full resource at drugs.com
Tags: Edema, Diabetes, Drug, Clinical Trial, News
Most Recently Shared on May 13, 2011 at 11:06 pm By:
pSivida Announces Resubmission of New Drug Application for Iluvien: WATERTOWN, Mass.--(BUSINESS WIRE)--May... http://bit.ly/m19oHW #drug
pSivida Announces Resubmission Of New Drug Application For ILUVIEN(R)
medicalnewstoday.com — “pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its licensee, Alimera Scien” View full resource at medicalnewstoday.com
Most Recently Shared on May 16, 2011 at 10:05 am By:
pSivida Announces Resubmission Of New Drug Application For ILUVIEN(R) http://mnt.to/3VTh #diabetes
Alimera receives FDA CRL for ILUVIEN NDA
news-medical.net — “pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN® for the treatment of Diabetic Macular Edema (DME), today announced that Alimera Sciences, Inc, pSivida's collaborative partner, received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ILUVIEN. The FDA issued the CRL to communicate its decision that” View full resource at news-medical.net
Most Recently Shared on December 24, 2010 at 8:27 am By:
Alimera receives FDA CRL for ILUVIEN NDA: pSivida Corp., a leader in developing sustained release, drug delivery... http://bit.ly/hnuJBP
pSivida announces FDA Priority Review status for Iluvien NDA
news-medical.net — “pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has been notified that the U.S. Food and Drug Administration (FDA) has granted Priority Review status for the New Drug Application (NDA) filed for Iluvien for the treatment diabetic macular edema (DME).” View full resource at news-medical.net
Most Recently Shared on August 31, 2010 at 1:26 pm By:
pSivida announces FDA Priority Review status for Iluvien NDA: pSivida Corp., a leader in the development of sustai... http://bit.ly/8YNXRu
Advertisement
